Literature DB >> 16888795

Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer.

Hojoong Kim1, Young Mi Kwon, Jin Seuk Kim, Joungho Han, Young Mog Shim, Joobae Park, Duk-Hwan Kim.   

Abstract

BACKGROUND: Despite many reports about the involvement of DNA methyltransferases (DNMTs) in human cancers, including nonsmall cell lung cancer (NSCLC), the clinicopathologic significance of DNMTs in primary NSCLC remains to be elucidated.
METHODS: The relation between the mRNA levels of DNMTs (1 and 3b) and the promoter methylation of the p16, RARbeta2, H-cadherin, GSTP1, RIZ, and FHIT genes and the clinicopathologic features in 102 fresh-frozen tissues and paraffin blocks were retrospectively studied. The mRNA levels of the DNMTs were assessed via semiquantitative reverse-transcription polymerase chain reaction (RT-PCR), and the methylation status of the CpG islands were determined by methylation-specific PCR.
RESULTS: The mRNA levels of DNMT1 and DNMT3b were elevated in 53% and 58% of 102 NSCLCs, respectively. Hypermethylation of p16, RARbeta2, H-cadherin, GSTP1, RIZ, and FHIT occurred in 37%, 38%, 34%, 18%, 9%, and 31% of patients, respectively. Univariate analysis showed that elevated DNMT mRNA levels were not significantly associated with the hypermethylation of 6 genes. However, the elevated mRNA levels of DNMT1 were determined to be significantly associated with the hypermethylation of the p16 promoter (odds ratio [OR] = 2.70, 95% confidence interval [95% CI], 1.02-7.15; P = .02), after controlling for age, gender, pack-years smoked, histology, and pathologic stage. The hazard of failure in cases with elevated mRNA levels of DNMT1 was 3.51 (95% CI, 1.18-12.76; P = .02) times higher than that in those without. The elevated mRNA levels of DNMT3b were not ultimately associated with patient prognosis.
CONCLUSIONS: Elevated mRNA expression of DNMT1 may be an independent prognostic factor in NSCLC and CpG island hypermethylation in NSCLC may be maintained by a complex interaction of several factors rather than by a simple transcriptional up-regulation of DNMT1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16888795     DOI: 10.1002/cncr.22087

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  Genetic variation in the promoter of DNMT3B is associated with the risk of colorectal cancer.

Authors:  Qian Bao; Bangshun He; Yuqin Pan; Zhipeng Tang; Ying Zhang; Lili Qu; Yongfei Xu; Chan Zhu; Fuliang Tian; Shukui Wang
Journal:  Int J Colorectal Dis       Date:  2011-04-26       Impact factor: 2.571

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  DNA methyltransferase expression differs with proliferation in childhood acute lymphoblastic leukemia.

Authors:  Derya Beyza Sayin; Emin Kürekçi; Halil Gürhan Karabulut; Ustün Ezer; Isik Bökesoy
Journal:  Mol Biol Rep       Date:  2009-09-10       Impact factor: 2.316

4.  hNaa10p contributes to tumorigenesis by facilitating DNMT1-mediated tumor suppressor gene silencing.

Authors:  Chung-Fan Lee; Derick S-C Ou; Sung-Bau Lee; Liang-Hao Chang; Ruo-Kai Lin; Ying-Shiuan Li; Anup K Upadhyay; Xiaodong Cheng; Yi-Ching Wang; Han-Shui Hsu; Michael Hsiao; Cheng-Wen Wu; Li-Jung Juan
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

Review 5.  Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

Authors:  K Ted Thurn; Scott Thomas; Amy Moore; Pamela N Munster
Journal:  Future Oncol       Date:  2011-02       Impact factor: 3.404

6.  Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.

Authors:  Linbo Gao; David Cheng; Jie Yang; Renyi Wu; Wenji Li; Ah-Ng Kong
Journal:  J Nutr Biochem       Date:  2018-02-09       Impact factor: 6.048

7.  Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy.

Authors:  Mingqing Tang; William Xu; Qizhao Wang; Weidong Xiao; Ruian Xu
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

8.  Association of the DNMT3B polymorphism with colorectal adenomatous polyps and adenocarcinoma.

Authors:  Xiaoqing Guo; Liwei Zhang; Mingli Wu; Na Wang; Yanfeng Liu; Limian Er; Shunping Wang; Yang Gao; Weifang Yu; Hui Xue; Zhibin Xu; Shijie Wang
Journal:  Mol Biol Rep       Date:  2009-07-22       Impact factor: 2.316

9.  MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B.

Authors:  Muller Fabbri; Ramiro Garzon; Amelia Cimmino; Zhongfa Liu; Nicola Zanesi; Elisa Callegari; Shujun Liu; Hansjuerg Alder; Stefan Costinean; Cecilia Fernandez-Cymering; Stefano Volinia; Gulnur Guler; Carl D Morrison; Kenneth K Chan; Guido Marcucci; George A Calin; Kay Huebner; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-21       Impact factor: 11.205

Review 10.  Epigenetics in non-small cell lung cancer: from basics to therapeutics.

Authors:  Junaid Ansari; Rodney E Shackelford; Hazem El-Osta
Journal:  Transl Lung Cancer Res       Date:  2016-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.